Cost of New PCSK9 Inhibitors May Overwhelm Patients and Payers

A new class of injectable cholesterol-lowering drugs, PCSK9 inhibitors, are good news for patients who are unresponsive to statins, but their current price. How will payers make this work? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 9/2/15)

You might also be interested in:

White House: Order Mandates Health Care Price Transparency June 28, 2019
Amgen to Cut Price of Cholesterol Drug by 60% October 26, 2018
ICER Releases Final New Evidence Update for Alirocumab February 15, 2019
Article: Price Drops on Praluent, Repatha Boon for Patients February 12, 2019
Study: Praluent Not Worth Price January 4, 2019
2018 Specialty Drug Trends February 4, 2019
Will Amgen's Repatha Price Cut Mesh with Value-Based Access? December 1, 2018